GlobeNewswire

Mandalay Resources Drills Multiple High-Grade Intercepts Beneath Historic Costerfield Mine, Victoria, Australia

Dela

TORONTO, April 03, 2018 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX:MND) is pleased to provide results from recent diamond drilling at its Costerfield Operations in Victoria, Australia.

This press release refers to tables and figures. The accompanying Table 2 can be found at the end of this press release, whereas the accompanying Figures 1, 2 and 3 can be found in an exploration presentation posted on the Company's website at the following address: http://www.mandalayresources.com/investor-presentations/#Technical_Presentations

Mandalay's recent and ongoing exploration drilling campaign on the property targets projections of veins beneath the historic Kendall and Costerfield mine, which was the largest historical producer in the district from 1864 to 1938 (Figure 1). Resulting intercepts demonstrate gold-antimony mineralization along a strike length of approximately 600 m and a dip length of approximately 200 m (Figures 2 and 3).

Highlights from drilling include the following six intercepts, which delineate a high-grade core of mineralization along the Costerfield Deeps projection measuring approximately 400 in strike by 150 m down-dip. The Company has named this emerging shoot the Youle vein after one of the three original prospectors in the district.

Table 1: Highlights of drill intercepts on the Youle Vein

Hole True Width 
(m)
Gold
(g/t)
Sb
(%)
AuEq (g/t) over
min. 1.8 m
mining width
BC021A 0.58   272.1 13.3 94.7
BC011 3.50 14.7 10.9 65.9
BC015 0.37   120.9 11.1 28.6
BC006W1 0.57 59.8   3.2 20.5
BC019 0.18 16.2   55.8 11.4
BC002 0.15 76.4   33.3 11.3

*Using metal prices of $1,400/oz Au and $10,000/t Sb
- AuEq(g/t) = Au(g) + Sb(%) x (Price per 10 Sb(kg) × Sb Recovery(%) )/(Price per 1 Au(g) × Au Recovery (%))

Mark Sander, President and Chief Executive Officer of Mandalay commented, "We are encouraged by the high-grade cluster of drill intercepts defining the core of the emerging Youle vein beneath the historic Costerfield mine. This setting is similar to the locations of the Augusta Lodes, the Cuffley Lode and the Brunswick Lode beneath other historic mines of the district, all of which Mandalay has converted to Mineral Reserves and has either mined or is preparing to mine.

"The drill hole intercepts of Youle reported in this press release contain some extraordinary gold and antimony grades that dilute to potentially minable gold equivalent grades over our minimum mining width of 1.8 m. As well, the strike length (400-600 m) and depth extent (150-200 m) of the intercepts are entirely consistent with the dimensions of orebodies we have found beneath the other historic mines in the district that have proved very profitable for Mandalay."   

Mr. Sander concluded, "There is room to grow this discovery along strike and down dip. The fact that Youle lies just several hundred metres to one kilometre from the Brunswick Lode, to which capital development access will be created later this quarter, suggests that there is potential to access the shoot quickly and for limited development capital. We plan to add additional surface rigs to the Youle drilling program to expand and infill high-grade mineralization as quickly as possible, with the goal of adding significantly to the Company's Mineral Resources and Reserves by the end of 2018."

Youle Drill Campaign History

Mandalay has drilled 27 diamond holes into the historic Costerfield mine area in three campaigns (2011, 2014 and 2017-2018). The Company reported significant early results from the Youle drill program in July, 2017 (see Mandalay July 24, 2017, press release).  Drilling accelerated in late 2017 after it was clear that Mandalay would commit to developing the Brunswick Lode, which will halve the distance to access Youle from then-limits of mining at Cuffley, and after significant advances were made in the understanding of the local mineralization. This program continued into 2018 with new results reported here leading to preliminary interpretation of Youle mineralization as a downward offset of the historically mined Costerfield Lode (Figures 2 and 3).

Drilling and Assaying

Diamond drill core was logged and sampled by Costerfield geologists. All samples were sent to Onsite Laboratory in Bendigo, Victoria, Australia, for sample preparation and assay. Site geological and metallurgical personnel have implemented a QA/QC process that includes the regular submission of standard reference materials and blanks with drill and face samples submitted for assay.  Standard reference materials have been certified by Geostats Pty Ltd. (see March 29, 2018, Technical Report entitled "Costerfield Operation, Victoria, Australia NI 43-101 Report", available on SEDAR (www.sedar.com), which contains a complete description of drilling, sampling, and assaying procedures.)

Table 2: Significant Drill Intercepts at Youle

Hole ID Hole
Completion
Date
Total
hole 
Depth
Intercept 
Easting 
(Mine 
Grid)
Intercept 
Northing 
(Mine
Grid)
Intercept
Elevation 
(Mine
Grid)
Drilled
Width
(m)
True
Width
(m)
Au 
Grade
(g/t)
Sb 
Grade
(%)
AuEq
(g/t)
Target
BC018 26/02/2018 402.0 15353 6523 1022 0.16 0.16 0.5 7.8 14.3 Youle Parallel Mineralization
BC017 14/02/2018 330.0 15339 6556 980 0.10 0.10 0.3 4.3 7.9 Youle
MB011 24/10/2011 480.0 15375 6629 914 0.07 0.06 130.9 44.6 209.4 Youle
MB011 24/10/2011 480.0 15369 6631 923 0.14 0.12 30.8 18.7 63.7 Youle Parallel Mineralization
BC001 8/07/2014 394.2 15399 6650 1007 0.10 0.07 3.1 0.8 4.5 Youle
BC013 23/01/2018 420.3 15326 6703 880 0.14 0.12 0.4 0.0 0.4 Youle
BC019 14/03/2018 386.9 15399 6745 952 0.18 0.18 16.2 55.8 114.4 Youle
BC007W1 5/06/2017 821.3 15235 6778 798 0.10 0.09 3.4 6.0 14.0 Youle
BC016 19/03/2018 401.7 15329 6786 854 0.21 0.17 9.6 14.3 34.8 Youle
BC002 18/06/2014 464.7 15372 6837 909 0.17 0.15 76.4 33.3 135.0 Youle
BC015 7/03/2018 431.7 15340 6925 834 0.47 0.37 120.9 11.1 140.4 Youle
BC006W1 29/06/2017 720.0 15362 6979 828 1.01 0.57 59.8 3.2 65.4 Youle
BC021A 21/03/2018 374.7 15408 6980 891 0.61 0.58 272.1 13.3 295.5 Youle
MB012 29/11/2011 475.3 15409 7047 895 0.15 0.10 94.1 19.3 128.1 Youle
BC010 3/01/2018 330.9 15450 7054 1002 0.19 0.10 6.8 13.7 31.0 Kendall West
BC010 3/01/2018 330.9 15445 7054 1008 0.27 0.14 21.1 12.5 43.1 Kendall West
BC011 17/01/2018 450.1 15394 7094 828 1.70 0.58 60.6 53.1 154.0 Youle
BC011* 17/01/2018 450.1 15394 7094 828 10.24 3.50 14.7 10.9 33.9 Youle Extended Composite
BC011W2 6/02/2018 395.7 15410 7126 858 0.32 0.08 9.1 5.4 18.6 Youle
BC014 7/03/2018 500.6 15373 7185 789 1.17 0.64 2.5 1.5 5.2 Youle West Splay
BC014 7/03/2018 500.6 15378 7185 756 0.23 0.15 0.3 1.0 1.9 Youle
BC014W1 19/01/2018 389.4 15384 7189 846 0.92 0.64 0.6 0.8 2.0 Youle West Splay
BC014W1 19/01/2018 389.4 15400 7191 810 0.11 0.10 0.7 7.4 13.7 Youle West Splay

Notes:
* Inclusive of other BC011 intercept.
- Using metal prices of $1,400/oz Au and $10,000/t Sb
- True width is preliminary estimate only and may not reflect final true width used in resource
- AuEq(g/t) = Au(g) + Sb(%) x (Price per 10 Sb(kg) × Sb Recovery(%) )/(Price per 1 Au(g) × Au Recovery (%))

Qualified Person:

Chris Gregory, Vice President of Operational Geology and Exploration at Mandalay Resources, is a Member of the Australian Institute of Geoscientists (AIG), and a Qualified Person as defined by NI 43-101. He has reviewed and approved the technical and scientific information provided in this release.

For Further Information:

Mark Sander
President and Chief Executive Officer

Greg DiTomaso
Director of Investor Relations

Contact: 647.260.1566

About Mandalay Resources Corporation:

Mandalay Resources is a Canadian-based natural resource company with producing assets in Australia and Sweden, and care and maintenance and development projects in Chile. The Company is focused on executing a roll-up strategy, creating critical mass by aggregating advanced or in production gold, copper, silver and antimony projects in Australia, the Americas and Europe to generate near-term cash flow and shareholder value.

Forward-Looking Statements:

This news release contains "forward-looking statements" within the meaning of applicable securities laws. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, changes in commodity prices and general market and economic conditions. The factors identified above are not intended to represent a complete list of the factors that could affect Mandalay. A description of additional risks that could result in actual results and developments differing from those contemplated by forward-looking statements in this news release can be found under the heading "Risk Factors" in Mandalay's annual information form dated March 29, 2018, a copy of which is available under Mandalay's profile at www.sedar.com. In addition, there can be no assurance that any inferred resources that are discovered as a result of additional drilling will ever be upgraded to proven or probable reserves. Although Mandalay has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Mandalay Resources Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum